- Home
- ACRV
as 10-17-2024 4:00pm EST
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 225.8M | IPO Year: | 2022 |
| Target Price: | $22.60 | AVG Volume (30 days): | 103.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.19 - $11.90 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Acrivon Therapeutics Inc. News
ACRV Breaking Stock News: Dive into ACRV Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 hours ago
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
GlobeNewswire
a day ago
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TipRanks
6 days ago
Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline
MT Newswires
7 days ago
Acrivon Therapeutics Reports First Patient Dosed in Phase 1 Trial of ACR-2316
GlobeNewswire
7 days ago
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
MT Newswires
a month ago
Ladenburg Thalmann Upgrades Acrivon Therapeutics to Buy From Neutral
GlobeNewswire
a month ago
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
GlobeNewswire
a month ago
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
Compare ACRV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACRV Acrivon Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.